The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Smoking Cessation Needed for Hep C Population

Back to News Homepage

Next

7 Tips for Tick Prevention

New HCV Combination Treatment for Only $300 in Lower-Income Countries

April 13, 2018

Print this page

Learn more about ravidasvir/sofosbuvir treatment, a new 12-week course of daily Hepatitis C treatment that was demonstrated in clinical trials to completely stamp out traces of HCV from 97 percent of the study’s patients.

Non-Profit’s $300 Hepatitis C Cure Rivals Current $48,000-Plus Options

An international medical non-profit organization has teamed up with an Egyptian drug manufacturer to develop a hepatitis C combination treatment that boasts cure rates comparable to the leading market pharmaceuticals – at less than 1 percent of the price.

Drugs for Neglected Diseases initiative (DNDi) released a statement on results from a clinical trial assessing the efficacy of ravidasvir – a new antiviral – taken with sofosbuvir, an existing medication. Set to be presented today at the International Liver Conference in Paris prior to publication in a journal, the dataset showed that a 12-week course of daily ravidasvir/sofosbuvir treatment completely eradicated traces of the virus from 97 percent of the study’s 301 patients, including those with the most severe forms of infection.

Continue reading this entire article:
http://www.iflscience.com/health-and-medicine/nonprofits-300-hepatitis-c-cure-rivals-current-48000plus-options/

No Comments - be the first!
Share
Share

Previous

Smoking Cessation Needed for Hep C Population

Back to News Homepage

Next

7 Tips for Tick Prevention

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.